{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:55:40Z","timestamp":1761519340710,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007476","name":"Diabetes Canada","doi-asserted-by":"publisher","award":["NC-3-18-5412"],"award-info":[{"award-number":["NC-3-18-5412"]}],"id":[{"id":"10.13039\/100007476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.diabres.2021.109177","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T23:09:37Z","timestamp":1639696177000},"page":"109177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Care gaps in achieving cholesterol targets in people with diabetes: A population-based study in a universal health care setting"],"prefix":"10.1016","volume":"184","author":[{"given":"Sonia","family":"Butalia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuli","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2021.109177_b0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"Supplement 1","key":"10.1016\/j.diabres.2021.109177_b0010","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc21-S010","article-title":"Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"9607","key":"10.1016\/j.diabres.2021.109177_b0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Collaborators","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.diabres.2021.109177_b0020","doi-asserted-by":"crossref","unstructured":"The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(1349e57).","DOI":"10.1056\/NEJM199811053391902"},{"issue":"9374","key":"10.1016\/j.diabres.2021.109177_b0025","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Heart Protection Study Collaborative Group","year":"2003","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2021.109177_b0030","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.diabres.2021.109177_b0035","doi-asserted-by":"crossref","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Dyslipidemia. Can J Diabetes. 2013;37:S110\u2013S116.","DOI":"10.1016\/j.jcjd.2013.01.032"},{"key":"10.1016\/j.diabres.2021.109177_b0040","unstructured":"Alberta College of Family Physicians. Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta 2017. Edmonton2017."},{"key":"10.1016\/j.diabres.2021.109177_b0045","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.jcjd.2017.10.019","article-title":"Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Dyslipidemia","volume":"42","author":"Mancini","year":"2018","journal-title":"Can J Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2021.109177_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1758-5996-6-117","article-title":"Sex-based disparities in cardioprotective medication use in adults with diabetes","volume":"5","author":"Butalia","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2021.109177_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2021.109177_b0060","unstructured":"Government of Alberta. Pharmaceutical Information Network (PIN) Frequently Asked Questions. 2017; http:\/\/www.albertanetcare.ca\/LearningCentre\/PIN-FAQ.htm. Accessed January 23, 2019."},{"issue":"3","key":"10.1016\/j.diabres.2021.109177_b0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2021.109177_b0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dise"},{"issue":"6","key":"10.1016\/j.diabres.2021.109177_b0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2021.109177_b0080","doi-asserted-by":"crossref","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.diabres.2021.109177_b0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"25, Part B","key":"10.1016\/j.diabres.2021.109177_b0090","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am College Cardiol"},{"key":"10.1016\/j.diabres.2021.109177_b0095","series-title":"Proceedings of the 2007 SAS Global Forum","article-title":"Using arrays to calculate medication utilization","author":"Leslie","year":"2007"},{"issue":"8","key":"10.1016\/j.diabres.2021.109177_b0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.18553\/jmcp.2016.22.8.892","article-title":"Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol","volume":"22","author":"Bellows","year":"2016","journal-title":"J Managed Care Specialty Pharmacy"},{"issue":"4","key":"10.1016\/j.diabres.2021.109177_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10557-018-6810-1","article-title":"Trends in Statin Use 2009\u20132015 in a Large Integrated Health System: Pre- and Post-2013 ACC\/AHA Guideline on Treatment of Blood Cholesterol","volume":"32","author":"Harrison","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.diabres.2021.109177_b0110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","article-title":"Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.diabres.2021.109177_b0115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2021.109177_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdiacomp.2017.09.014","article-title":"Longitudinal trends and predictors of statin use among patients with diabetes","volume":"32","author":"Brennan","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.diabres.2021.109177_b0125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.amjcard.2019.07.002","article-title":"Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease","volume":"124","author":"Chamberlain","year":"2019","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.diabres.2021.109177_b0130","first-page":"884","article-title":"Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta","volume":"35","author":"Chen","year":"2019","journal-title":"Can J Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2021.109177_b0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","article-title":"Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Managed Care Specialty Pharmacy"},{"key":"10.1016\/j.diabres.2021.109177_b0140","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/PPA.S231873","article-title":"Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia","volume":"13","author":"Alwhaibi","year":"2019","journal-title":"Patient Preference Adherence"},{"issue":"11","key":"10.1016\/j.diabres.2021.109177_b0145","doi-asserted-by":"crossref","first-page":"e2025505","DOI":"10.1001\/jamanetworkopen.2020.25505","article-title":"Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016","volume":"3","author":"Yao","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.diabres.2021.109177_b0150","doi-asserted-by":"crossref","first-page":"e010376","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to Statin Therapy Among US Adults Between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.diabres.2021.109177_b0155","first-page":"e005562","article-title":"Sex Differences in the Use of Statins in Community Practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabres.2021.109177_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjco.2020.07.002","article-title":"Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians","author":"Butalia","year":"2020","journal-title":"CJC Open"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721005374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721005374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:18:53Z","timestamp":1759173533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721005374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":32,"alternative-id":["S0168822721005374"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.109177","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Care gaps in achieving cholesterol targets in people with diabetes: A population-based study in a universal health care setting","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.109177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109177"}}